Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux.
Under the liquidity agreement entrusted by MaaT Pharma to Kepler Cheuvreux, the following resources were listed on the liquidity account on December 31st, 2023:
- 24,236 shares
- 34,107.60
- Number of executions on buy side on semester: 627
- Number of executions on sell side on semester: 368
- Traded volume on buy side on semester: 18,328 shares for 122,340.49
- Traded volume on sell side on semester: 9,576 shares for 64,693.03
As a reminder:
- the following resources appeared on the last half year statement on June 30, 2023 on the liquidity account:
- 15,484 shares
- 41,285.13
- Number of executions on buy side on semester: 552
- Number of executions on sell side on semester: 431
- Traded volume on buy side on semester: 15,974 shares for 144,745.75
- Traded volume on sell side on semester: 12,997 shares for 122,384.16
The following resources appeared on the liquidity account when the activity started:
- 0 shares
- 200,000.00
The liquidity contract has been in effect since March 14, 2022, in accordance with the authorization granted by the General Meeting on March 3, 2022, and renewed on June 19, 2023. The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22, 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice.
| Buy side | Sell side | ||||||
| Number of executions | Number of shares | Traded volume in EUR | Number of executions | Number of shares | Traded volume in EUR | ||
| Total | 627 | 18,328 | 122,340.49 | 368 | 9,576 | 64,693.03 | |
| 03/07/2023 | 5 | 447 | 3,111.12 | ||||
| 04/07/2023 | 21 | 845 | 5,391.10 | ||||
| 05/07/2023 | 4 | 284 | 1,848.84 | 1 | 1 | 6.90 | |
| 06/07/2023 | 4 | 111 | 747.03 | 1 | 1 | 6.84 | |
| 07/07/2023 | 3 | 70 | 466.20 | ||||
| 10/07/2023 | 1 | 50 | 335.00 | ||||
| 12/07/2023 | 1 | 30 | 201.00 | ||||
| 13/07/2023 | 3 | 20 | 133.00 | ||||
| 14/07/2023 | 1 | 1 | 6.62 | 1 | 1 | 6.62 | |
| 17/07/2023 | 3 | 110 | 715.00 | ||||
| 18/07/2023 | 3 | 100 | 640.00 | ||||
| 19/07/2023 | 1 | 20 | 128.00 | 2 | 40 | 258.40 | |
| 20/07/2023 | 1 | 40 | 256.00 | 1 | 50 | 323.00 | |
| 21/07/2023 | 1 | 40 | 256.00 | ||||
| 24/07/2023 | 1 | 30 | 192.60 | ||||
| 25/07/2023 | 2 | 21 | 134.40 | 1 | 1 | 6.40 | |
| 26/07/2023 | 2 | 51 | 325.38 | 1 | 1 | 6.38 | |
| 27/07/2023 | 1 | 50 | 320.00 | 4 | 66 | 423.72 | |
| 28/07/2023 | 3 | 100 | 633.00 | 2 | 54 | 345.60 | |
| 31/07/2023 | 3 | 100 | 621.00 | 3 | 71 | 454.40 | |
| 01/08/2023 | 1 | 50 | 320.00 | 4 | 129 | 833.34 | |
| 02/08/2023 | 2 | 80 | 508.00 | ||||
| 03/08/2023 | 3 | 50 | 320.00 | ||||
| 04/08/2023 | 5 | 31 | 195.30 | 1 | 1 | 6.30 | |
| 07/08/2023 | 1 | 20 | 128.00 | ||||
| 08/08/2023 | 1 | 20 | 128.00 | ||||
| 09/08/2023 | 2 | 24 | 152.16 | ||||
| 10/08/2023 | 1 | 1 | 6.38 | 1 | 1 | 6.38 | |
| 11/08/2023 | 1 | 1 | 6.38 | 2 | 7 | 44.80 | |
| 14/08/2023 | 4 | 50 | 315.00 | ||||
| 15/08/2023 | 1 | 1 | 6.32 | 2 | 31 | 198.40 | |
| 16/08/2023 | 3 | 31 | 195.30 | 1 | 1 | 6.38 | |
| 17/08/2023 | 1 | 10 | 63.00 | 1 | 20 | 128.00 | |
| 18/08/2023 | 2 | 21 | 132.30 | 1 | 1 | 6.38 | |
| 21/08/2023 | 2 | 50 | 320.00 | ||||
| 22/08/2023 | 2 | 41 | 258.30 | 1 | 1 | 6.38 | |
| 23/08/2023 | 3 | 30 | 188.70 | 2 | 60 | 382.20 | |
| 24/08/2023 | 3 | 30 | 189.00 | 1 | 20 | 128.00 | |
| 25/08/2023 | 6 | 116 | 709.92 | 5 | 94 | 579.98 | |
| 28/08/2023 | 5 | 90 | 547.20 | 2 | 11 | 69.30 | |
| 29/08/2023 | 4 | 31 | 192.20 | 3 | 48 | 304.32 | |
| 30/08/2023 | 6 | 370 | 2,353.20 | ||||
| 31/08/2023 | 5 | 109 | 683.43 | ||||
| 05/09/2023 | 1 | 1 | 6.30 | 1 | 1 | 6.30 | |
| 06/09/2023 | 1 | 1 | 6.32 | 1 | 1 | 6.32 | |
| 07/09/2023 | 7 | 248 | 1,550.00 | 3 | 150 | 969.00 | |
| 08/09/2023 | 5 | 244 | 1,520.12 | 2 | 151 | 966.40 | |
| 11/09/2023 | 2 | 6 | 38.04 | ||||
| 12/09/2023 | 7 | 344 | 2,132.80 | 4 | 100 | 626.00 | |
| 13/09/2023 | 2 | 31 | 195.30 | 5 | 81 | 515.16 | |
| 14/09/2023 | 1 | 20 | 126.00 | 1 | 20 | 128.00 | |
| 18/09/2023 | 4 | 151 | 943.75 | 3 | 80 | 500.80 | |
| 19/09/2023 | 5 | 60 | 369.00 | 2 | 21 | 130.20 | |
| 20/09/2023 | 2 | 10 | 63.00 | 4 | 80 | 511.20 | |
| 21/09/2023 | 4 | 100 | 618.00 | 1 | 50 | 315.00 | |
| 22/09/2023 | 7 | 239 | 1,465.07 | 1 | 1 | 6.28 | |
| 25/09/2023 | 4 | 110 | 684.20 | 2 | 50 | 313.00 | |
| 26/09/2023 | 9 | 430 | 2,558.50 | 2 | 50 | 314.50 | |
| 27/09/2023 | 12 | 791 | 4,445.42 | 5 | 122 | 744.20 | |
| 28/09/2023 | 12 | 710 | 3,564.20 | 2 | 200 | 1,008.00 | |
| 29/09/2023 | 2 | 50 | 252.00 | 5 | 300 | 1,554.00 | |
| 02/10/2023 | 3 | 130 | 661.70 | ||||
| 03/10/2023 | 18 | 540 | 2,624.40 | 11 | 400 | 2,000.00 | |
| 04/10/2023 | 3 | 130 | 666.90 | 3 | 110 | 569.80 | |
| 05/10/2023 | 3 | 234 | 1,404.00 | 18 | 588 | 3,580.92 | |
| 06/10/2023 | 2 | 50 | 313.00 | 3 | 60 | 379.80 | |
| 09/10/2023 | 9 | 190 | 1,155.20 | ||||
| 10/10/2023 | 5 | 105 | 628.95 | 2 | 30 | 183.00 | |
| 11/10/2023 | 9 | 167 | 993.65 | 3 | 49 | 300.37 | |
| 12/10/2023 | 1 | 1 | 5.82 | 4 | 51 | 306.00 | |
| 13/10/2023 | 6 | 73 | 427.78 | 2 | 23 | 140.30 | |
| 16/10/2023 | 1 | 99 | 588.06 | 1 | 48 | 288.00 | |
| 17/10/2023 | 2 | 11 | 66.00 | 1 | 1 | 5.98 | |
| 18/10/2023 | 3 | 35 | 211.75 | 3 | 39 | 239.85 | |
| 19/10/2023 | 6 | 139 | 849.29 | 3 | 80 | 498.40 | |
| 20/10/2023 | 3 | 8 | 48.72 | 2 | 21 | 129.99 | |
| 23/10/2023 | 4 | 67 | 414.73 | 1 | 20 | 124.00 | |
| 24/10/2023 | 5 | 74 | 454.36 | 2 | 21 | 130.20 | |
| 25/10/2023 | 2 | 18 | 111.60 | 1 | 1 | 6.22 | |
| 26/10/2023 | 8 | 339 | 2,278.08 | ||||
| 27/10/2023 | 5 | 140 | 974.40 | 4 | 49 | 348.88 | |
| 30/10/2023 | 6 | 90 | 632.70 | 1 | 21 | 151.20 | |
| 31/10/2023 | 2 | 40 | 286.40 | 12 | 354 | 2,708.10 | |
| 01/11/2023 | 4 | 400 | 3,164.00 | 10 | 338 | 2,879.76 | |
| 02/11/2023 | 19 | 1,720 | 13,553.60 | ||||
| 03/11/2023 | 22 | 1,108 | 8,110.56 | ||||
| 06/11/2023 | 5 | 77 | 599.83 | 5 | 82 | 655.18 | |
| 07/11/2023 | 5 | 95 | 787.55 | 8 | 140 | 1,164.80 | |
| 08/11/2023 | 7 | 125 | 1,028.75 | 1 | 20 | 166.00 | |
| 09/11/2023 | 10 | 207 | 1,674.63 | 2 | 6 | 49.80 | |
| 10/11/2023 | 20 | 216 | 1,736.64 | 1 | 1 | 8.06 | |
| 13/11/2023 | 11 | 117 | 932.49 | ||||
| 14/11/2023 | 4 | 69 | 539.58 | 4 | 48 | 379.68 | |
| 15/11/2023 | 11 | 270 | 2,060.10 | 4 | 140 | 1,104.60 | |
| 16/11/2023 | 5 | 121 | 917.18 | 4 | 75 | 574.50 | |
| 17/11/2023 | 3 | 90 | 695.70 | ||||
| 20/11/2023 | 10 | 484 | 3,562.24 | 4 | 61 | 461.16 | |
| 21/11/2023 | 13 | 303 | 2,172.51 | 3 | 92 | 678.96 | |
| 22/11/2023 | 4 | 63 | 451.71 | 3 | 43 | 313.90 | |
| 23/11/2023 | 4 | 93 | 675.18 | ||||
| 24/11/2023 | 4 | 65 | 467.35 | ||||
| 27/11/2023 | 8 | 161 | 1,122.17 | 1 | 1 | 7.14 | |
| 28/11/2023 | 6 | 140 | 952.00 | 3 | 110 | 767.80 | |
| 29/11/2023 | 3 | 200 | 1,380.00 | 1 | 1 | 6.96 | |
| 30/11/2023 | 5 | 140 | 945.00 | 2 | 90 | 610.20 | |
| 01/12/2023 | 21 | 389 | 2,594.63 | 13 | 415 | 3,037.80 | |
| 04/12/2023 | 2 | 100 | 685.00 | 5 | 147 | 1,043.70 | |
| 05/12/2023 | 2 | 65 | 455.00 | ||||
| 06/12/2023 | 1 | 17 | 118.32 | 3 | 75 | 525.00 | |
| 07/12/2023 | 11 | 349 | 2,348.77 | 3 | 90 | 618.30 | |
| 08/12/2023 | 15 | 251 | 1,641.54 | 4 | 61 | 405.65 | |
| 11/12/2023 | 7 | 154 | 1,057.98 | 22 | 1,083 | 7,873.41 | |
| 12/12/2023 | 4 | 48 | 340.80 | 9 | 300 | 2,145.00 | |
| 13/12/2023 | 13 | 238 | 1,635.06 | ||||
| 14/12/2023 | 4 | 60 | 403.20 | 3 | 60 | 409.80 | |
| 15/12/2023 | 9 | 190 | 1,271.10 | 11 | 300 | 2,055.00 | |
| 18/12/2023 | 4 | 20 | 135.60 | 2 | 15 | 102.30 | |
| 19/12/2023 | 5 | 71 | 484.22 | 5 | 21 | 143.43 | |
| 20/12/2023 | 5 | 60 | 418.20 | 10 | 225 | 1,579.50 | |
| 21/12/2023 | 10 | 92 | 623.76 | 4 | 81 | 568.62 | |
| 22/12/2023 | 10 | 137 | 946.67 | 15 | 261 | 1,827.00 | |
| 27/12/2023 | 4 | 75 | 536.25 | 8 | 210 | 1,507.80 | |
| 28/12/2023 | 3 | 35 | 250.25 | 4 | 80 | 583.20 | |
| 29/12/2023 | 11 | 314 | 2,179.16 | 8 | 165 | 1,166.55 | |
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint®, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company's Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris (ticker: MAAT).
View source version on businesswire.com: https://www.businesswire.com/news/home/20240122876130/en/
Contacts:
MaaT Pharma Investor Relations
Guilhaume DEBROAS, Ph.D.
Head of Investor Relations
+33 6 16 48 92 50
invest@maat-pharma.com
MaaT Pharma Media Relations
Pauline RICHAUD
Senior PR Corporate Communications Manager
+33 6 14 06 45 92
media@maat-pharma.com
Trophic Communications Corporate Communications
Stephanie MAY or
Priscilla PERRIN
+49 171 351 2733
maat@trophic.eu
Trading-Plan 2024: Die Performance-Strategie für das neue Jahr
Der kostenfreie Trading-Plan von Stefan Klotter gibt Ihnen einen exklusiven Einblick, in welche Branchen, Sektoren und Assets Sie im Jahr 2024 investieren sollten, um eine satte Rendite zu erzielen. Jetzt sichern!
Hier klicken
I have a deep understanding of the topic at hand, particularly in the field of biotechnology and financial aspects related to companies like MaaT Pharma. My expertise is rooted in my extensive knowledge of clinical-stage biotechnology companies and their operational dynamics.
Now, regarding the information in the article about MaaT Pharma:
-
Liquidity Contract with Kepler Cheuvreux:
- The liquidity contract between MaaT Pharma and Kepler Cheuvreux involves a liquidity account with specific details.
- The resources listed on the liquidity account on December 31, 2023, include 24,236 shares and a total traded volume on both buy and sell sides, along with the corresponding execution numbers.
- The liquidity contract has been in effect since March 14, 2022, following authorization granted by the General Meeting on March 3, 2022, and renewed on June 19, 2023.
- The report's implementation aligns with the AMF Decision N°2021-01 of June 22, 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice.
-
Detailed Trading Activity:
- The article provides a breakdown of the trading activity on both buy and sell sides throughout the semester, including the number of executions, number of shares, and traded volume in EUR for each date.
-
Historical Data Comparison:
- A comparison is made with the liquidity account statement on June 30, 2023, indicating changes in shares, executions, and traded volumes over the semester.
-
Buy and Sell Side Summary:
- The summary table at the end presents a comprehensive overview of the buy and sell side activities, consolidating the number of executions, number of shares, and traded volume on both sides.
-
MaaT Pharma Overview:
- The article concludes with information about MaaT Pharma, its clinical-stage status, focus on Microbiome Ecosystem Therapies, and ongoing clinical trials for conditions like acute GvHD.
This detailed information showcases MaaT Pharma's financial interactions, trading activities, and its commitment to microbiome-related therapies in the field of oncology and stem cell transplantation.
